Description: The SOA Research Institute along with the International Section, and the Social Insurance and Public Finance Section are pleased to make available a research report that compares international and domestic mandated paid family and medical leave programs. Special thanks to both Sections for their sponsorship of this effort.

Description: This study evaluates how integrating social determinants of health (SDOH) into Medicaid risk adjustment models impacts financial outcomes for ACOs/MCOs, offering foundational insights for policymakers and actuaries.

Description: This document explores how climate change impacts retirement planning, investments, housing, and health across policy and economic dimensions through essays and funded research.

Description: This collection presents three essays analyzing the multifaceted impacts of AI and LLMs on retirees and retirement professionals, blending quantitative, philosophical, and forward-looking perspectives.

Description: This webcast will update listeners on the financial status of the U.S. Social Security program, describe half a dozen widespread myths, and discuss the reality of "waste, fraud and abuse" in the program.

Description: Update from the life insurance industry trade's perspective on tax policy and political issues

Description: This report details the 2025 HMI and FMI scale recommendations for individual life insurance mortality valuation under AG38 and VM20 using insured population data.

Description: A biennial survey analyzing financial risk awareness and retirement transition experiences of Americans aged 45–80.

Description: Guidance and a model for actuaries to use when performing their professional services related to Medicaid (Title XIX) and Children’s Health Insurance Program (CHIP or Title XXI) managed care capitation rate setting.

Description: Develop a better understanding of specialty drug trends and their increasing healthcare costs for more than the past decade by attending this webcast. With the introduction of price competition, you will see changes in the market for biosimilar products and patent-protected drugs. For example, the drug Humira will be gaining 10 biosimilar competitors in 2023. Alone, Humira can represent over 20% of total pharmacy spend for health plans. Join us and discover how price competition is a turning point for the pharmaceutical industry and will define its direction for the next decade.